89Zr-labeled HER2-targeted antibody fragment
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for 89Zr-labeled HER2-targeted antibody fragment, covering 2025-06-17 to 2025-06-17. Get the full timeline:
Most recent: Clinical Trial Update: PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors [EARLY_Phase 1]